• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NIH awards $17.9 million for blinding diseases research

NIH awards $17.9 million for blinding diseases research

May 1, 2015
CenterWatch Staff

The National Eye Institute (NEI) has awarded five projects funds to develop new technology to noninvasively image cells of the eye as part of its Audacious Goals Initiative. NEI has committed $3.8 million to the projects in 2015 and up to $17.9 million over the next five years, pending the availability of funds. NEI is part of the National Institutes of Health.

The NEI Audacious Goals Initiative is a coordinated effort to spur new therapies for blinding diseases. The central goal is to restore vision by regenerating neurons and neural connections in the eye and visual system. Special emphasis is devoted to cells of the retina, including the light-sensitive rod and cone photoreceptors, and the retinal ganglion cells, which connect photoreceptors to the brain via the optic nerve.

“These ambitious projects will give us a window into the visual system,” said Paul A. Sieving, M.D., Ph.D., NEI director. “Tools developed will enhance the study of functional changes in the retina and optic nerve, in real-time and at the cellular level, and will be indispensable when evaluating new regenerative therapies for eye diseases.”

Many causes of incurable blindness affect retinal neurons. Among the hundreds of rare inherited disorders that damage the retina are retinitis pigmentosa and Stargardt disease. Common causes include age-related macular degeneration and glaucoma.

“We have entered the research phase of the Audacious Goals Initiative. Projects in this first round of AGI funding will bridge gaps in current technology, enabling later phases of the initiative,” said Sieving.

The five projects include:

  • Interferometric Optophysiology of the Human Retina. Principal Investigator Austin Roorda, Ph.D., University of California, Berkeley
  • Accelerating Vision Restoration with In-vivo Cellular Imaging of Retinal Function. Principal Investigator David Williams, Ph.D., University of Rochester Center for Visual Science, NY
  • A Two-photon Ophthalmoscope for Human Retinal Imaging and Functional Testing. Principal Investigator Krzysztof Palczewski, Ph.D., Case Western Reserve University, Cleveland
  •  Imaging Optic Nerve Function and Pathology. Principal Investigators Sheng-Kwei Song, Ph.D., and Yong Wang, Ph.D., Washington University, St. Louis
  • Platform Technologies for Microscopic Retinal Imaging: Development and Translation. Principal Investigators Alfredo Dubra, Ph.D., and Joseph Carroll, Ph.D., Medical College of Wisconsin, Milwaukee.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing